abstract: Oral contraceptives are one of the most frequently used forms of birth control among young women. However, research has shown that this type of medication can contribute to negative changes in mood and diminished vitamin status. In particular, women taking oral contraceptives are at an increased risk of vitamin B6 deficiency due to changes in enzyme activity with estrogen intake. Depressed mood is one of the known symptoms of vitamin B6 deficiency as this vitamin acts as an essential cofactor in converting tryptophan to the neurotransmitter, serotonin. Lack of adequate levels of vitamin B6 therefore contribute to decreased production of serotonin and subsequent changes in mood, including symptoms of depression. With vitamin B6 being the most common nutrient deficiency, and the ever increasing prevalence of depression in the United States, especially among young adults, it is crucial that researchers investigate ways to mitigate both of these undesirable side effects. Current research on the topic fails to directly connect supplementation of vitamin B6 to positive changes in mood in oral contraceptive users. This 12-week long double-blinded, placebo-controlled crossover trial examined the effects of daily supplementation of vitamin B6 as 100 mg of pyridoxine hydrochloride, on mood states in 8 healthy college women (18-25 y) that use combined oral contraceptives. Vitamin status was assessed via plasma pyridoxal 5’-phosphate (PLP). Plasma PLP levels significantly increased by >193% (p=0.003) with daily supplementation of 100 mg B6 over a four week period. Mood changes with supplementation were assessed using the Profile of Mood States (POMS). Although a small improvement in the POMS depression sub score was observed after 4 weeks of vitamin B6 supplementation (14.7%), the changes were insignificant (p>0.05). Furthermore, total mood disturbance scores did not significantly change with either the placebo or supplement periods. While mood states were not improved, a significant decrease in the presence of depressive symptoms as measured by the Beck Depression Inventory was observed after vitamin B6 supplementation, compared to placebo (p=0.047). The results of this study necessitate further investigation into the use of B6 supplementation as a means of reducing negative mood changes in oral contraceptive users. / Dissertation/Thesis / Masters Thesis Nutrition 2020

No description available.

Diethylstilbestrol (DES) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) have been identified as immunotoxicants causing thymic atrophy, thymocyte hypocellularity, phenotypic changes detected by CD4 and CD8 surface antigens, and progenitor T-cell targeting in the fetal mouse. We hypothesized that gestational exposure to these two compounds may lead to comparable histologic and gene expression alterations in the fetal mouse thymus and liver. Treatment of pregnant C57Bl/6 mice with doses of 5 or 10 ug/kg TCDD or 48 ug/kg DES by oral gavage on gestation days (gd) 14 and 16 severely depressed day 18 thymic cellularity. Histologic evaluation of day 18 fetal thymuses showed disruption of normal cortico-medullary architecture after TCDD or DES. Decreased thymocyte density was noted primarily in cortical zones where pyknotic cells were increased by either TCDD or DES treatment. Using day 18 thymocyte suspensions and flow cytometry, 7-AAD showed decreases in viable thymocytes from TCDD- or DES-treated fetal mice, and concomitant increases in thymocytes in early apoptosis. When thymocytes were co-identified with CD4 and CD8 cell surface antigen expression, enhanced apoptosis occurred in CD4+CD8+ phenotype after TCDD treatment. After DES exposure, increased apoptosis occurred in CD4-CD8- and CD4-CD8+thymocytes. Both TCDD and DES increased liver to body weight ratios and decreased ratios of hematopoietic to hepatic cells present. Cytomegaly was seen in hepatocytes of TCDD and DES treated animals, and these cells had more variable features, such as increased cytoplasmic basophilia and more prominent nucleoli. Real time quantitative PCR demonstrated that DES decreased c-jun, Bcl-2, and PKCalpha mRNA expression. These results suggest a shift away from proliferative activity and may reflect alterations noted predominantly in the hematopoietic population. TCDD increased c-jun mRNA expression with modest decreases in PKCalpha, and marked decreases in p53 also noted. Decreases in p53 suggest a pro-proliferative status of hepatic cells, while decreases in PKCalpha may indicate decreases in phosphorylation of substrates required for normal cell cycle progression. The increased c-jun suggests that this gene may play a role in the hepatocyte hyperplasia, as well as the diminution of hematopoiesis. / Ph. D.

M.S.

The vitamin B-6 status of 11 white adolescent females living in the Blacksburg/Roanoke, Virginia area was evaluated by dietary intakes, coenzyme stimulation of erythrocyte alanine aminotransferase (F-ALAT) activities, and plasma total vitamin B-6 measured microbiologically. Heights and weights of the group were generally within ranges. The vitamin B-6 intakes of the adolescents were 1.47 ± 0.49 mg/day (mean ± SD). Three subjects, or 27.3%, the same subjects classified as inadequate in status by coenzyme stimulation of E-ALAT, were classified as marginal or inadequate in status using ≤ 25 ng/ml total plasma vitamin B-6 levels as the criterion. The plasma pyridoxal, pyridoxine, pyridoxamine and total B-6 vitamer concentrations of subjects having inadequate E-ALAT values were lower, generally significantly, than those of girls with adequate levels. In the subjects with adequate status, the vitamer found in the largest plasma concentration was pyridoxine. A significant correlation (r = 0.82, p < 0.01) was observed between total plasma vitamin B-6 levels determined microbiologically and coenzyme stimulation values. / Master of Science

The purpose of this study was to compare the nutrient content of a new instant baby food product to jar baby food of similar product formulation. Instant and jar "Vegetable and Beef" and "Bananas" products processed in 1985 and 1987 were analyzed for available lysine, vitamin B-6 and pyridoxyllysine content. The available lysine content of 100 grams of baby food was found to be higher in the instant products, but when adjusted for protein content, available lysine was higher in the jar products. This indicates that drum-drying used for the instant products is more detrimental in regard to lysine availability than retorting. The vitamin B-6 content of the instant products was found to be higher than that of the jar products. However, due to the addition of ingredients with little or no vitamin B-6 content to the jar products, no conclusion about processing effects on vitamin B-6 content can be made. Products processed in 1985 tended to be lower in nutrient content than the products processed in 1987. Pyridoxyllysine, a compound thought to affect vitamin B-6 bioavailability, could not be detected in any of the baby foods, either by amino acid or HPLC analysis. The instant products were found to be at least equal to the jar products with regard to available lysine and vitamin B-6 content. All products also appear to provide sufficient amounts of these nutrients to infants less than one year of age. / Master of Science

The influence of vitamin B-6 intake on vitamin B-6 status and the concentration of B-6 vitamers in milk of 21 white lactating women (21 to 35 years) was examined at 3 to 7 months postpartum. None of the women met the RDA for lactating women of 2.5 mg/day when considering vitamin B-6 intakes from food sources alone. All subjects taking vitamin B-6 supplements had adequate vitamin B-6 status as determined by coenzyme stimulation of erythrocyte alanine aminotransferase activity; all subjects not taking vitamin B-6 supplements had inadequate vitamin B-6 status. Plasma pyridoxal 5-phosphate values were significantly higher for subjects in the supplemented than in the nonsupplemented group. Pyridoxal, pyridoxamine, pyridoxine, and total vitamin B-6 concentrations in milk were higher, sometimes significantly, in the supplemented than in the unsupplemented group as determined by microbiological assay and HPLC. There were significant correlations between data obtained by the microbiological and HPLC analyses for pyridoxal and total vitamin B-6 concentrations. Pyridoxal was the predominant B-6 vitamer found in human milk. Distribution of the B-6 vitamers appeared to stay relatively constant despite vitamin B-6 status. / Master of Science

The growth of many breast cancers is stimulated by the action of the hormone estrogen. Hormonal therapy used to treat these estrogen-dependent breast cancers acts by interfering with the action of estrogen. Current treatments, such as tamoxifen, are not consistently useful due to development of resistance to these drugs. Tamoxifen treatment can also lead to the development of other gynecological cancers, therefore the discovery of novel treatment options for breast cancer is critical. Vitamin B6 is well documented for its role as a modulator of steroid hormones. Pyridoxal phosphate (PLP), the active form of Vitamin B6, may interfere with the action of the estrogen receptor (ER) by blocking the hormone-binding and/or DNA-binding site of the ER. The objective of this study was to examine the effects of Vitamin B6 supplementation on cell proliferation and estrogen-dependent gene expression in breast cancer cells. To accomplish this, estrogen-dependent (MCF-7 and T-47D) and estrogen-independent (BT-20) breast cancer cells were grown in medium supplemented with 0,100, or 300 µM pyridoxal (PL) in the absence or presence of 0.01µM estradiol. Cell counts and [3H]-thymidine incorporation into DNA were assessed in all cell lines. The expression of pS2, an estrogen-sensitive gene, was performed using RNA extracted from MCF-7 cells. PL supplementation was found to significantly decrease total cell numbers and DNA synthesis in both the estrogen-dependent (ER+) and -independent (ER-) breast cancer cells, but did not alter the expression of pS2. These results indicate that PL significantly impairs growth of breast cancer cells and may be exerting its effects via a steroid-independent mechanism. / Master of Science

The problem of this study is to determine the vitamin B-6 status of patients who have chronic obstructive pulmonary disease (COPD). Erythrocyte aspartate transaminase assay was the method for measuring vitamin B-6 status. The vitamin B-6 status was examined in thirty subjects (ten COPD subjects and twenty control subjects). An unpaired t-test was used to compare the vitamin B-6 status of the COPD group versus the control group. Four determinants (percentage stimulation, ratio of basal to stimulated activity, basal activity, and stimulated activity) were used to determine vitamin B-6 status in both groups of subjects. Percentage stimulation and ratio of basal to stimulated activity were not significantly different (control group versus COPD group) at the .05 level. However, two of ten COPD subjects had values for percentage stimulation that were two standard deviations above the mean, indicating a poor B-6 status. In contrast, basal activity and stimulated activity of erythrocyte aspartate transaminase were found to be significantly lower at the .05 level in the COPD group than the control group. Therefore, the COPD subjects as a group had some biochemical characteristics of a lower level of vitamin B-6 than the controls.

A acne é uma doença de pele com alta prevalência e seu tratamento é importante para evitar lesões cutâneas permanentes ou o agravamento de transtornos psicológicos provenientes do abalo à autoestima. Dessa forma, o desenvolvimento de formulações dermocosméticas eficazes que possam melhorar as condições desse tipo de pele é de grande valia. Dentre os ativos com potenciais benefícios para o controle de alguns dos principais fatores causadores da acne, estão a vitamina B3, um derivado de vitamina B6 e o PCA zinco. Assim o objetivo deste estudo foi o desenvolvimento de formulações dermocosméticas para a pele acnéica contendo vitamina B3, derivado lipossolúvel de vitamina B6 e PCA zinco bem como a avaliação da estabilidade e eficácia clínica dessas formulações. Para tal, foram desenvolvidas diferentes formulações, as quais, em um primeiro momento, foram avaliadas quanto à estabilidade frente à adição do ingrediente ativo Zinc PCA. Após esta etapa, os demais ingredientes ativos foram adicionados e as formulações foram submetidas a testes preliminares de estabilidade e ao estudo da estabilidade física por determinação do comportamento reológico. A formulação mais estável foi avaliada quanto à compatibilidade cutânea e também em relação à comedogenicidade do veículo. A formulação composta pelos ingredientes ativos foi avaliada, ainda, quanto as suas características sensoriais e eficácia clínica. Os estudos de eficácia foram realizados por meio de métodos objetivos e subjetivos, após seis semanas do uso da formulação. Os métodos objetivos consistiram no uso de metodologias in vivo, não invasivas (métodos biofísicos e de imagem), sendo avaliados parâmetros relacionados à hidratação, função barreira, conteúdo lipídico, pH cutâneo, contagem de porfirinas, de microcomedões e de lesões inflamatórias. Em relação aos métodos subjetivos, foi realizada a percepção da eficácia por meio de um questionário para a comparação da pele antes e após o tratamento. Os resultados mostraram que, de todas as formulações desenvolvidas, apenas uma mostrou-se estável frente aos testes de estabilidade realizados. A formulação (veículo e adicionada de ingredientes ativos) apresentou compatibilidade cutânea considerada como \"muito boa\", de acordo com o teste realizado, e o veículo sem potencial comedogênico. Na avaliação sensorial as frequências obtidas para os parâmetros considerados como ruins foram baixas, indicando que o sensorial da formulação mostrou-se adequado para as finalidades propostas. No estudo de eficácia clínica, a formulação não alterou a hidratação e a função barreira da pele e mostrou-se eficaz na redução da contagem de porfirinas e das lesões inflamatórias (p<0,05). A avaliação clínica por métodos subjetivos mostrou a eficácia da formulação quanto à melhora da acne inflamatória, oleosidade da pele, hidratação e maciez. Por fim, os resultados obtidos mostraram que a formulação desenvolvida é eficaz e compatível com a pele, bem como a importância da pesquisa e desenvolvimento para a obtenção de formulações estáveis, seguras, eficazes e com sensorial adequado. / Acne is a skin disease with high prevalence and its treatment is important to prevent permanent skin lesions or the aggravation of psychological disorders due to self-esteem shaken. This way, the development of effective dermocosmetic formulations, that can improve the conditions of this skin type, is very important. Vitamin B3, a vitamin B6 derivative and zinc PCA are among the active ingredients which present potential benefits in the controlling of some pathogenic factors of acne. Thus, the aim of this research was to develop cosmetic formulations for acneic skin containing vitamin B3, vitamin B6 lipophilic derivative and zinc PCA, as well as the evaluation of stability and clinical efficacy. For this purpose, were developed different formulations which, at first, were evaluated in terms of stability face to zinc PCA addition. After this, the others active ingredients were added and the formulations were submitted to preliminary tests of stability and physical stability studies by rheological behavior determination. The most stable formulation was subject to skin compatibility evaluation and vehicle comedogenicity. The formulation with the active ingredients was also evaluated regarding their sensorial characteristics and clinical efficacy. Efficacy studies were performed by means of objective and subjective methods, after a sixweek- period of use of the formulation. The objective methods consisted in non-invasive in vivo methodologies (biophysical techniques and image analysis) where were evaluated hydration, barrier function, lipid content, skin pH and the counting of porphyrins, microcomedones and inflammatories lesions. In relation to subjective methods, was performed the efficacy perception using a questionnaire in order to compare the skin before and after the treatment. The results showed that among the formulations developed, only one kept stable after the stability tests. The formulations were considered as \"very good\" on skin compatibility test and showed no comedogenic potential. In sensorial evaluation, frequencies obtained for the parameters considered bad were low, which indicate the sensorial of the formulation was adequate for the purposes. In clinical efficacy study, the formulation under study did not alter the parameters related to hydration and skin barrier function and was effective in reducing the counting of porphyrins and inflammatories lesions (p<0,05). Clinical evaluation by subjective methods showed the formulation effectiveness regarding the improvement of inflammatory acne, skin oiliness, hydration and softness. Finally, the results obtained showed the formulation developed is effective and compatible with the skin and, besides the importance of research and development for obtaining stable, safe and effective formulations with suitable sensorial.